Please login to the form below

Biosimilars - the Brexit of the pharmaceutical industry?

In this article, Senior Consultant Jenna Earl explains what factors influence the uptake of biosimilars in the UK, comparing them to the same principles that help us navigate the complexities of Britain exiting the EU (Brexit).
Despite availability of biosimilars for nearly a decade, uptake in the UK is still lagging behind other EU markets, leading to the recent formation of the British Biosimilars Association (BBA) - part of the British Generic Manufacturers Association (BGMA). Biosimilars are undoubtedly a hot topic for providers of branded biologic medicines, biosimilar suppliers themselves, and the payers, healthcare professionals and patients involved in biologic treatment. Much like the EU referendum, they feature regularly in the news - with spectators waiting anxiously, in some cases eagerly, for a change that could alter the treatment landscape for several significant therapy areas. To understand the factors influencing the uptake of biosimilars you could apply the same principles as you would to navigating the complexities of Britain exiting the EU (Brexit).

1. Control is in the hands of the people

Britain's relationship with the EU will be decided by a referendum, placing the decision in the hands of the people. In the UK, the decision to prescribe a biosimilar is still largely down to the healthcare professional (HCP) but, if this were to change, impact on biologic markets could be dramatic. Despite NICE recommending biosimilars ahead of branded biologics in several disease areas, this does not appear to be happening in clinical practice. The next step for governing bodies to ensure biosimilars are prioritised in the treatment pathway is substitution, replacing a branded biologic with its corresponding biosimilar at point of dispensing; a move that would result in a huge uplift in biosimilar use. Arguably, the reason this hasn’t happened yet is that the financial gain generated by such a move does not yet outweigh the repercussions of reducing the role of the HCP in such an important decision. But with increasing pressure on the NHS to make cost savings and expect greater value from treatments, this could change in the future. 

Read the full article on the Blue Latitude Health blog

14th June 2016

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health
Crusader House
145-157 St John Street
London
EC1V 4QJ
United Kingdom

Latest content on this profile

Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine.
Blue Latitude Health
Behavioural insights to navigate complex healthcare markets
Blue Latitude Health Head of Insight Martine Leroy reveals how her team uses behavioural insights to help develop strong pharma brands and services, which successfully navigate complex situations.
Blue Latitude Health
Biotech: it's a people business
Nancy Hunter is the Marketing Director at a cutting-edge pharmaceutical company. Here she explains how a sharp focus on patients’ needs is driving a new operating model for marketing first-in-class drugs, and she describes how her mother’s experience as a cancer patient has shaped her own outlook on healthcare.
Blue Latitude Health
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges and opportunities while introducing the latest issue of 'Perspective' magazine on this weighty topic.
Blue Latitude Health
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively.
Blue Latitude Health
Does your medical information service work for your users?
Customer Experience Consultant Nilu Davies reveals how you can ensure your medical information service is fit for purpose.
Blue Latitude Health